We have determined the ability of the endothelin (ET)A receptor antagonist, PD156707 (CI 1020), to inhibit intimal proliferation in human saphenous veins maintained in organ culture. After 28 days in culture, veins exposed to 1µM PD156707 exhibited a significant reduction in intima to intima-plus-media ratio (I:I+M ratio) (0.14±0.02, n = 15) and an increase in lumen area (3.1±0.8mm2) compared with veins cultured without the antagonist (I:I+M, 0.29±0.02; lumen area, 2.5±0.7mm2; n = 23) but were not significantly different from pre-cultured controls (I:I+M, 0.15±0.02; lumen area, 4.4±1.2mm2; n = 17) (Dunn's test for non-parametric multiple comparisons: α<0.05). In organ bath experiments, ET-1 and 5-hydroxytryptamine constricted pre-cultured control vessels with pD2 values (where pD2 is defined as the negative logarithm of the molar EC50 value of an agonist) of 8.9±0.4 and 7.0±0.4 (n = 3) and Emax (efficacy) values of 86±3% and 71±13% (compared with constriction induced by KCl) respectively. There was no difference in the responsiveness of veins cultured for 14 days to either agonist, indicating that the vessels maintained in organ culture remain viable. Crucially, vein segments cultured with 1µM PD156707 (a concentration that antagonized ET-1 responses in pre-cultured control vessels) contracted to ET-1 with a potency comparable to that obtained in vessels cultured in the absence of the antagonist (pD2 = 8.9±0.4 and 8.0±0.6 respectively, n = 3) confirming that PD156707 was not toxic to the tissue at the concentration used. In conclusion we have shown that the ETA-selective antagonist, PD156707, completely blocked intimal hyperplasia in human saphenous veins in organ culture, suggesting that ETA antagonists may be beneficial in preventing or delaying saphenous vein graft disease in patients receiving bypass grafts for coronary artery disease.
Skip Nav Destination
Article navigation
September 2002
-
Cover Image
Cover Image
Conference Article|
September 01 2002
ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels
Janet J. MAGUIRE;
1Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, U.K.
Dr J. J. Maguire (e-mail [email protected]).
Search for other works by this author on:
Julie C.-M. YU;
Julie C.-M. YU
1Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, U.K.
Search for other works by this author on:
Anthony P. DAVENPORT
Anthony P. DAVENPORT
1Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2002 The Biochemical Society and the Medical Research Society
2002
Clin Sci (Lond) (2002) 103 (s2002): 184S–188S.
Citation
Janet J. MAGUIRE, Julie C.-M. YU, Anthony P. DAVENPORT; ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clin Sci (Lond) 1 September 2002; 103 (s2002): 184S–188S. doi: https://doi.org/10.1042/CS103S184S
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |